Zevra Therapeutics (ZVRA) Research & Development: 2014-2025
Historic Research & Development for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $3.4 million.
- Zevra Therapeutics' Research & Development fell 68.64% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 59.09%. This contributed to the annual value of $42.1 million for FY2024, which is 5.75% up from last year.
- Zevra Therapeutics' Research & Development amounted to $3.4 million in Q3 2025, which was down 0.03% from $3.4 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Research & Development ranged from a high of $12.3 million in Q3 2023 and a low of $2.2 million during Q3 2021.
- Its 3-year average for Research & Development is $8.4 million, with a median of $8.7 million in 2023.
- In the last 5 years, Zevra Therapeutics' Research & Development spiked by 180.82% in 2023 and then slumped by 73.46% in 2025.
- Zevra Therapeutics' Research & Development (Quarterly) stood at $2.8 million in 2021, then spiked by 132.86% to $6.5 million in 2022, then soared by 74.61% to $11.4 million in 2023, then declined by 26.87% to $8.4 million in 2024, then tumbled by 68.64% to $3.4 million in 2025.
- Its Research & Development was $3.4 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.3 million in Q1 2025.